BioSpace News Archive

BLDG Active™, the leader in bringing environmentally responsible cutting-edge medical technologies to the active outdoor community, has added two physicians to its team. Dr. Shakha Gillin, MD, FAAP, board-certified pediatrician and Vishakha Gigler, MD, board-certified dermatologist, join the rapidly growing brand bringing a breadth of medical expertise and hands-on clinical experience.

Pharmacists are accessible providers who can help patients with various health care needs

The global electrocautery devices market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report by Technavio.

More Than $10M Total Foundation Support For Babson Healthcare Initiatives

With the federal election campaign entering its 3rd week, the Canadian Medical Association welcomes today’s commitment by the Liberal Party of Canada to boost federal investment in health care.

ImagineMIC™ announces the launch of a groundbreaking new telehealth solution to revolutionize patient care in skilled nursing environments

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform won the 2019 Spine Technology Award presented by Orthopedics This Week, a widely read publication in the orthopedics industry

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2019 third quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, October 22, 2019, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

Titan Medical Inc. announced that it has filed and been receipted for a preliminary short form prospectus with securities regulators in the provinces of Ontario, British Columbia and Alberta.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported the first set of results from Week 96 of the RESCUE Phase III clinical trial.